Marty
Well-known member
MedPage Today (8/18, Bankhead) reported that "cientists who helped track down the source of contaminated heparin earlier this year have cleared a hurdle in a quest to produce a safe and potent synthetic version of the blood thinner." Robert Linhardt, Ph.D., of Rensselaer Polytechnic Institute in Troy, N.Y., reported at the American Chemical Society meeting that, "[d]erived from Escherichia coli, the synthetic heparin, can now be produced in milligram quantities, a necessary step toward batch production." Linhardt said that synthetic heparin "would be manufactured totally in a controlled, laboratory environment, eliminating the potential for contamination with current production methods for heparin, which primarily comes from pigs."
At the meeting, Linhardt "described a new method of heparin biosynthesis that has produced amounts measured in milligrams," HealthDay (8/18, Edelson) added. It is Linhardt's hope, however, "that production can be scaled up a million-fold."
At the meeting, Linhardt "described a new method of heparin biosynthesis that has produced amounts measured in milligrams," HealthDay (8/18, Edelson) added. It is Linhardt's hope, however, "that production can be scaled up a million-fold."
